Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine

Daniele Mei, Diana Ferraro, Giovanni Zelano, Alessandro Capuano, Catello Vollono, Carbone Gabriele, Girolamo Di Trapani

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

OBJECTIVE: This is a randomized, double-blind versus placebo study aimed at evaluating the efficacy of topiramate (TPM) in reducing the number of days with headache and the amount of acute medication taken monthly in patients with chronic migraine with medication overuse. We also studied the efficacy of single triptans available in Italy in interrupting headache crises during preventive treatment. METHODS: The studied sample was made up of 50 subjects: 30 patients were randomized for treatment with TPM, 100 mg/d, and 20 for placebo. Subjects treated with TPM were further randomized to evaluate, in double-blind versus placebo, the efficacy of single triptans available in Italy. The double-blind phase consisted of a titration phase (4 weeks) and of a maintenance phase (8 weeks). OUTCOME MEASURES: The reduction in the number of days with headache per 28 days and the reduction in the amount of acute medication taken per 28 days throughout the clinical trial in the TPM group were compared with those of the placebo group; the number of patients who were pain-free at 2 hours after the triptan intake and the headache recurrence rate in the 22 hours after the pain-free condition in the triptan group were compared with those of the placebo group. We also looked at tolerability profile. RESULTS: The group treated with TPM had a significant reduction in the number of days with headache (P <0.0001 vs placebo) and in the mean amount of acute medication taken (P <0.0001 vs placebo); all triptans were superior to placebo; there were no significant differences between different triptans; the analgesic effect of triptans increased throughout the trial. CONCLUSIONS: Topiramate proved to be well tolerated and effective in reverting chronic migraine with medication overuse to episodic migraine.

Original languageEnglish
Pages (from-to)269-275
Number of pages7
JournalClinical Neuropharmacology
Volume29
Issue number5
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Tryptamines
Migraine Disorders
Placebos
Headache
Italy
Prescription Drug Overuse
topiramate
Analgesics
Maintenance
Clinical Trials
Recurrence

Keywords

  • Chronic migraine
  • Cortical hyperexcitability
  • Medication overuse
  • Topiramate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. / Mei, Daniele; Ferraro, Diana; Zelano, Giovanni; Capuano, Alessandro; Vollono, Catello; Gabriele, Carbone; Di Trapani, Girolamo.

In: Clinical Neuropharmacology, Vol. 29, No. 5, 09.2006, p. 269-275.

Research output: Contribution to journalArticle

Mei, Daniele ; Ferraro, Diana ; Zelano, Giovanni ; Capuano, Alessandro ; Vollono, Catello ; Gabriele, Carbone ; Di Trapani, Girolamo. / Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. In: Clinical Neuropharmacology. 2006 ; Vol. 29, No. 5. pp. 269-275.
@article{fa0c029673344f70ad0e1553002aed29,
title = "Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine",
abstract = "OBJECTIVE: This is a randomized, double-blind versus placebo study aimed at evaluating the efficacy of topiramate (TPM) in reducing the number of days with headache and the amount of acute medication taken monthly in patients with chronic migraine with medication overuse. We also studied the efficacy of single triptans available in Italy in interrupting headache crises during preventive treatment. METHODS: The studied sample was made up of 50 subjects: 30 patients were randomized for treatment with TPM, 100 mg/d, and 20 for placebo. Subjects treated with TPM were further randomized to evaluate, in double-blind versus placebo, the efficacy of single triptans available in Italy. The double-blind phase consisted of a titration phase (4 weeks) and of a maintenance phase (8 weeks). OUTCOME MEASURES: The reduction in the number of days with headache per 28 days and the reduction in the amount of acute medication taken per 28 days throughout the clinical trial in the TPM group were compared with those of the placebo group; the number of patients who were pain-free at 2 hours after the triptan intake and the headache recurrence rate in the 22 hours after the pain-free condition in the triptan group were compared with those of the placebo group. We also looked at tolerability profile. RESULTS: The group treated with TPM had a significant reduction in the number of days with headache (P <0.0001 vs placebo) and in the mean amount of acute medication taken (P <0.0001 vs placebo); all triptans were superior to placebo; there were no significant differences between different triptans; the analgesic effect of triptans increased throughout the trial. CONCLUSIONS: Topiramate proved to be well tolerated and effective in reverting chronic migraine with medication overuse to episodic migraine.",
keywords = "Chronic migraine, Cortical hyperexcitability, Medication overuse, Topiramate",
author = "Daniele Mei and Diana Ferraro and Giovanni Zelano and Alessandro Capuano and Catello Vollono and Carbone Gabriele and {Di Trapani}, Girolamo",
year = "2006",
month = "9",
doi = "10.1097/01.WNF.000022888.49044.99",
language = "English",
volume = "29",
pages = "269--275",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine

AU - Mei, Daniele

AU - Ferraro, Diana

AU - Zelano, Giovanni

AU - Capuano, Alessandro

AU - Vollono, Catello

AU - Gabriele, Carbone

AU - Di Trapani, Girolamo

PY - 2006/9

Y1 - 2006/9

N2 - OBJECTIVE: This is a randomized, double-blind versus placebo study aimed at evaluating the efficacy of topiramate (TPM) in reducing the number of days with headache and the amount of acute medication taken monthly in patients with chronic migraine with medication overuse. We also studied the efficacy of single triptans available in Italy in interrupting headache crises during preventive treatment. METHODS: The studied sample was made up of 50 subjects: 30 patients were randomized for treatment with TPM, 100 mg/d, and 20 for placebo. Subjects treated with TPM were further randomized to evaluate, in double-blind versus placebo, the efficacy of single triptans available in Italy. The double-blind phase consisted of a titration phase (4 weeks) and of a maintenance phase (8 weeks). OUTCOME MEASURES: The reduction in the number of days with headache per 28 days and the reduction in the amount of acute medication taken per 28 days throughout the clinical trial in the TPM group were compared with those of the placebo group; the number of patients who were pain-free at 2 hours after the triptan intake and the headache recurrence rate in the 22 hours after the pain-free condition in the triptan group were compared with those of the placebo group. We also looked at tolerability profile. RESULTS: The group treated with TPM had a significant reduction in the number of days with headache (P <0.0001 vs placebo) and in the mean amount of acute medication taken (P <0.0001 vs placebo); all triptans were superior to placebo; there were no significant differences between different triptans; the analgesic effect of triptans increased throughout the trial. CONCLUSIONS: Topiramate proved to be well tolerated and effective in reverting chronic migraine with medication overuse to episodic migraine.

AB - OBJECTIVE: This is a randomized, double-blind versus placebo study aimed at evaluating the efficacy of topiramate (TPM) in reducing the number of days with headache and the amount of acute medication taken monthly in patients with chronic migraine with medication overuse. We also studied the efficacy of single triptans available in Italy in interrupting headache crises during preventive treatment. METHODS: The studied sample was made up of 50 subjects: 30 patients were randomized for treatment with TPM, 100 mg/d, and 20 for placebo. Subjects treated with TPM were further randomized to evaluate, in double-blind versus placebo, the efficacy of single triptans available in Italy. The double-blind phase consisted of a titration phase (4 weeks) and of a maintenance phase (8 weeks). OUTCOME MEASURES: The reduction in the number of days with headache per 28 days and the reduction in the amount of acute medication taken per 28 days throughout the clinical trial in the TPM group were compared with those of the placebo group; the number of patients who were pain-free at 2 hours after the triptan intake and the headache recurrence rate in the 22 hours after the pain-free condition in the triptan group were compared with those of the placebo group. We also looked at tolerability profile. RESULTS: The group treated with TPM had a significant reduction in the number of days with headache (P <0.0001 vs placebo) and in the mean amount of acute medication taken (P <0.0001 vs placebo); all triptans were superior to placebo; there were no significant differences between different triptans; the analgesic effect of triptans increased throughout the trial. CONCLUSIONS: Topiramate proved to be well tolerated and effective in reverting chronic migraine with medication overuse to episodic migraine.

KW - Chronic migraine

KW - Cortical hyperexcitability

KW - Medication overuse

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=33748968518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748968518&partnerID=8YFLogxK

U2 - 10.1097/01.WNF.000022888.49044.99

DO - 10.1097/01.WNF.000022888.49044.99

M3 - Article

C2 - 16960472

AN - SCOPUS:33748968518

VL - 29

SP - 269

EP - 275

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -